Saxenda vs Wegovy: Which GLP-1 for Weight Loss?

Saxenda and Wegovy are both GLP-1 options for weight management, but the daily-versus-weekly routine changes the experience as much as the trial results do. This comparison is most useful when you look at schedule fit, side effects, and what is realistic to maintain.

What are Saxenda and Wegovy?

Saxenda and Wegovy are both injectable prescription medications approved by the FDA for chronic weight management in adults with obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Both are meant to be used alongside a reduced-calorie diet and increased physical activity.

Saxenda contains liraglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes under the brand name Victoza. Saxenda was approved for weight management in 2014. It is also approved for adolescents aged 12 to 17 with a body weight above 60 kg (132 lbs) and obesity.

Wegovy contains semaglutide, a newer GLP-1 receptor agonist approved for weight management in June 2021. Semaglutide is also the active ingredient in Ozempic (approved for type 2 diabetes) and is now available as an oral Wegovy pill as well. In March 2024, Wegovy received an additional FDA approval for reducing the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity or overweight.

How do Saxenda and Wegovy work differently?

Both medications mimic GLP-1 (glucagon-like peptide-1), a natural hormone that regulates appetite, slows stomach emptying, and helps control blood sugar. By activating GLP-1 receptors in the brain, both drugs reduce hunger and help people feel full sooner and for longer after eating.

The key pharmacological difference is structural. Liraglutide (Saxenda) shares 97% of its amino acid sequence with natural human GLP-1 and has a half-life of approximately 13 hours, which is why it must be injected every day. Semaglutide (Wegovy) was engineered with additional modifications that extend its half-life to approximately 7 days, allowing for once-weekly dosing. This longer half-life also means semaglutide maintains more consistent drug levels in the body between doses.

How do the dosing schedules compare?

Both medications use a gradual dose escalation to reduce gastrointestinal side effects, but their schedules differ significantly in frequency and duration.

Saxenda starts at 0.6 mg injected once daily. The dose increases by 0.6 mg each week until reaching the target maintenance dose of 3 mg per day, which takes approximately 5 weeks. If a patient has not achieved at least a 4% reduction in body weight after 16 weeks on the 3 mg maintenance dose, the FDA prescribing information recommends that the prescriber consider discontinuing treatment.

Wegovy starts at 0.25 mg injected once weekly. The dose increases every 4 weeks through 0.5 mg, 1 mg, and 1.7 mg before reaching the maintenance dose of 2.4 mg per week. The full escalation takes approximately 16 to 20 weeks. For a comparison of Wegovy with other semaglutide products, see our Wegovy vs Ozempic guide.

How much weight loss can you expect with each medication?

The most important evidence comes from the STEP 8 trial, published in JAMA in January 2022. This was the first randomized head-to-head clinical trial directly comparing semaglutide 2.4 mg weekly with liraglutide 3 mg daily for weight loss. The trial enrolled 338 adults with overweight or obesity (BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity) without diabetes.

After 68 weeks, participants taking semaglutide (Wegovy) lost an average of 15.8% of their body weight, compared to 6.4% with liraglutide (Saxenda). The difference of 9.4 percentage points was statistically significant (P < 0.001).

In terms of clinically meaningful thresholds, approximately 70% of participants on Wegovy achieved at least 10% weight loss, compared to about 25% on Saxenda. About 55% of the Wegovy group achieved at least 15% weight loss, compared to roughly 12% on Saxenda. These results indicate that Wegovy produces substantially greater weight loss on average.

Broader clinical trial data supports these findings. Across the STEP trial program, Wegovy 2.4 mg consistently produced average weight loss of 15% to 17% of body weight. In the SCALE trials for Saxenda, liraglutide 3 mg produced average weight loss of approximately 5% to 8% of body weight over 56 weeks.

What are the side effects of Saxenda vs Wegovy?

Both medications share similar gastrointestinal side effects because they act on the same GLP-1 pathway. The most common adverse events are nausea, vomiting, diarrhea, and constipation, which tend to be most pronounced during the dose-escalation period and usually improve over time.

Although gastrointestinal side effects were somewhat more common with Wegovy in clinical trials, discontinuation rates due to adverse events were actually higher with Saxenda. In the STEP 8 head-to-head trial, 3.2% of participants on semaglutide stopped treatment due to side effects, compared to 12.6% on liraglutide.

Both medications carry a boxed warning about the risk of thyroid C-cell tumors (observed in rodent studies) and share serious warnings for pancreatitis, gallbladder disease, acute kidney injury, and suicidal thoughts or behavior. Neither medication should be used by people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Talk to your healthcare provider about your full medical history before starting either medication.

How much do Saxenda and Wegovy cost?

Both medications are manufactured by Novo Nordisk and carry significant out-of-pocket costs without insurance coverage. The list price for brand-name Saxenda is approximately $1,300 to $1,500 per month. A generic version of liraglutide may be available at some pharmacies at a lower price point, typically around $370 to $1,300 per month depending on the pharmacy and location.

Wegovy's pricing has changed in recent years. As of late 2025, Novo Nordisk lowered the self-pay price for Wegovy to $349 per month for the injection and $299 per month for the oral pill through its savings program. With commercial insurance that covers Wegovy, copays may be as low as $0 to $25 per month through the manufacturer's savings card.

Insurance coverage for weight-loss medications varies widely. Many commercial plans still do not cover GLP-1 medications prescribed specifically for weight management. Medicare Part D generally does not cover medications prescribed solely for weight loss, though coverage policies continue to evolve. Patients should check with their specific insurance plan and consider manufacturer savings programs.

Which medication is right for you?

The choice between Saxenda and Wegovy depends on several individual factors, and the decision should always be made with a healthcare provider. Here are the main considerations.

Wegovy may be a better fit for people who prefer a once-weekly injection over a daily one, want stronger average weight loss results based on clinical trial data, or have cardiovascular disease and could benefit from Wegovy's proven heart-health benefits (demonstrated in the SELECT trial).

Saxenda may be considered when Wegovy is not covered by a patient's insurance but Saxenda is, when a patient has experienced side effects on semaglutide and wants to try a different GLP-1, or for adolescents aged 12 to 17 (Saxenda has a longer track record in this age group, though Wegovy also has FDA approval for teens aged 12 and older).

It is important to note that you should not take both Saxenda and Wegovy at the same time, as combining two GLP-1 receptor agonists increases the risk of serious side effects. If switching between the two, your healthcare provider will guide you on the appropriate transition.

How can you track your GLP-1 medication and progress?

Whether you are taking a daily or weekly injection, consistency is key to getting the best results. Important things to monitor include your current dose and titration schedule, injection site rotation (abdomen, thigh, or upper arm), side effects — especially during dose increases, and body weight and other health metrics over time.

Glone is a free iOS app built specifically for GLP-1 medication tracking. It includes smart injection site rotation reminders, dose schedule tracking for both daily and weekly medications, and AI-powered food analysis to help you make informed dietary choices while on treatment.

Sources

• FDA Prescribing Information for Saxenda (liraglutide) injection 3 mg — accessdata.fda.gov
• FDA Prescribing Information for Wegovy (semaglutide) injection 2.4 mg — accessdata.fda.gov
• STEP 8 Trial — Rubino et al., "Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes," JAMA 2022 — pubmed.ncbi.nlm.nih.gov
• STEP 1 Trial — Wilding et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," NEJM 2021 — nejm.org
• Saxenda Side Effects and Clinical Trial Data — novomedlink.com
• Wegovy Chronic Weight Management Trial Results — novomedlink.com